Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA172379)
Received: 22 May 2018
Accepted: 17 December 2018
First Online: 23 April 2019
: C.L. and D.S.W. have partial ownership in a private venture, Epionc Inc., incorporated to develop small-molecule inhibitors for cancer treatment. In accord with University of Kentucky policies, C.L. and D.S.W. have disclosed this work to the University of Kentucky’s Intellectual Property Committee and complied with stipulations of the University’s Conflict of Interest Oversight Committee.